(:MYOV)

Nov 05, 2023 04:39 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myovant Sciences, Ltd. - MYOV
Pomerantz LLP is investigating claims on behalf of investors of Myovant Sciences, Ltd. (“Myovant” or the “Company”) (NASDAQ: MYOV).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....
Oct 27, 2023 01:21 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myovant Sciences, Ltd. - MYOV
Pomerantz LLP is investigating claims on behalf of investors of Myovant Sciences, Ltd. (“Myovant” or the “Company”) (NASDAQ: MYOV).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....
Oct 03, 2023 12:40 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myovant Sciences, Ltd. - MYOV
Pomerantz LLP is investigating claims on behalf of investors of Myovant Sciences, Ltd. (“Myovant” or the “Company”) (NASDAQ: MYOV).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....
Sep 29, 2023 05:48 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myovant Sciences, Ltd. - MYOV
NEW YORK, Sept. 29, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Myovant Sciences, Ltd. ("Myovant" or the "Company") (NYSE: MYOV). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Sep 26, 2023 04:32 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myovant Sciences, Ltd. - MYOV
Pomerantz LLP is investigating claims on behalf of investors of Myovant Sciences, Ltd. (“Myovant” or the “Company”) (NASDAQ: MYOV).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....
Jan 26, 2023 04:05 pm ET
Myovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 2022
Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and men through purpose-driven science, empowering medicines, and transformative advocacy, today announced financial results for the third quarter of...
Jan 26, 2023 11:20 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SAFE, LBAI, FCRD, MYOV
NEW YORK, Jan. 26, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jan 25, 2023 01:04 pm ET
MYOVANT SCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Myovant Sciences - MYOV
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Myovant Sciences (NYSE: MYOV) to Sumitomo Pharma Co., Ltd. Under the terms of the proposed transaction, shareholders of Myovant will receive only $27.00 in cash for each share of Myovant that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Jan 12, 2023 01:05 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LBAI, IMRA, MYOV, IAA
NEW YORK, Jan. 12, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jan 11, 2023 05:43 pm ET
MYOVANT SCIENCES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Myovant Sciences - MYOV
NEW ORLEANS, Jan. 11, 2023 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Myovant Sciences (NYSE: MYOV) to Sumitomo Pharma Co., Ltd. Under the terms of the proposed transaction, shareholders of Myovant will receive only $27.00 in cash for each share of Myovant that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Dec 18, 2022 05:32 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MYOV, AIMC, APEN
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Myovant Sciences Ltd. (NYSE: MYOV)’s...
Dec 16, 2022 07:00 am ET
MYOV SPECIAL ALERT: Julie & Holleman Investigates Potential Legal Claims Related to Take-Private Acquisition of Myovant Sciences
NEW YORK, Dec. 16, 2022 /PRNewswire/ -- Shareholder rights law firm Julie & Holleman is investigating the proposed acquisition of Myovant Sciences (NYSE: MYOV) by affiliates of its controlling shareholder, Sumitovant Biopharma, an affiliate of Japanese conglomerate Sumitomo. Under the terms of the deal, Sumitovant will acquire all the outstanding shares of Myovant common stock it does not already own for $27 per share in cash, or a total of approximately $1.7 billion.
Dec 11, 2022 11:30 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MMX, OFIX, MYOV, PEBO
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Maverix Metals Inc. (NYSE: MMX)’s...
Dec 10, 2022 08:07 pm ET
Lifshitz Law PLLC Announces Investigations of BNFT, IMGO, MYOV, and HVBC
Benefitfocus, Inc. (NASDAQ: BNFT) Lifshitz Law PLLC announces investigation into possible breach of fiduciary duties in connection with the sale of BNFT to Voya Financial, Inc. for $10.50 per share. If you are a BNFT investor, and...
Dec 01, 2022 10:40 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates JVA, PEBO, MYOV, POSH, OIIM
NEW YORK, Dec. 1, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Nov 30, 2022 07:46 pm ET
Lifshitz Law PLLC Announces Investigations of BNFT, IMGO, MYOV, and HVBC
Benefitfocus, Inc. (NASDAQ: BNFT) Lifshitz Law PLLC announces investigation into possible breach of fiduciary duties in connection with the sale of BNFT to Voya Financial, Inc. for $10.50 per share. If you are a BNFT investor, and would...
Nov 27, 2022 10:26 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPNT, WAFD, MYOV
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Opiant Pharmaceuticals, Inc. (NASDAQ:...
Nov 24, 2022 11:16 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LFG, MYOV, PEBO, LMST
NEW YORK, Nov. 24, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Nov 20, 2022 10:45 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AYLA, MYOV, USER, AGFS
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Ayala Pharmaceuticals, Inc. (NASDAQ:...
Nov 19, 2022 08:07 pm ET
Lifshitz Law PLLC Announces Investigations of BNFT, ATCO, MYOV, and HVBC
Benefitfocus, Inc. (NASDAQ: BNFT) Lifshitz Law PLLC announces investigation into possible breach of fiduciary duties in connection with the sale of BNFT to Voya Financial, Inc. for $10.50 per share. If you are a BNFT investor, and would like...
Nov 16, 2022 04:45 pm ET
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced that it approved equity awards for 18...
Nov 16, 2022 06:45 am ET
Myovant Sciences Appoints Ann Tomlin as Senior Vice President of Human Resources
Myovant Sciences (NYSE: MYOV) today announced the appointment of Ann Tomlin as Senior Vice President of Human Resources. Beginning November 28, Ms. Tomlin will be responsible for developing talent solutions and human resources strategies across...
Nov 13, 2022 01:55 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FORG, IMRA, LFG, MYOV
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: ForgeRock, Inc. (NYSE: FORG)’s sale to...
Nov 10, 2022 09:35 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OFIX, AAWW, AVEO, MYOV
NEW YORK, Nov. 10, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Nov 09, 2022 07:11 pm ET
Lifshitz Law PLLC Announces Investigations of BNFT, ATCO, MYOV, and HVBC
Benefitfocus, Inc. (NASDAQ: BNFT) Lifshitz Law PLLC announces investigation into possible breach of fiduciary duties in connection with the sale of BNFT to Voya Financial, Inc. for $10.50 per share. If you are a BNFT investor, and would like...
Nov 02, 2022 12:28 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AKUS, MYOV, PEBO
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Akouos, Inc. (NASDAQ: AKUS)’s sale to...
Oct 31, 2022 06:25 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVEO, PEBO, LMST, MYOV
NEW YORK, Oct. 31, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Oct 31, 2022 12:47 pm ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) Myovant Sciences Ltd. (NYSE - MYOV), ForgeRock, Inc. (NYSE - FORG), SeaSpine Holdings Corporation (Nasdaq - SP
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Oct 27, 2022 09:57 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ECOM, MYOV, PEBO, LMST
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: ChannelAdvisor Corporation (NYSE:...
Oct 26, 2022 08:30 am ET
Myovant Sciences Announces Corporate Updates and Financial Results for Second Fiscal Quarter 2022
Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced financial results for the second...
Oct 25, 2022 09:51 pm ET
MYOVANT SCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Myovant Sciences - MYOV
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Myovant Sciences (NYSE: MYOV) to Sumitomo Pharma Co., Ltd. Under the terms of the proposed transaction, shareholders of Myovant will receive only $27.00 in cash for each share of Myovant that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Oct 25, 2022 10:30 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LMST, PEBO, HVBC, MYOV, AGTC
NEW YORK, Oct. 25, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Oct 24, 2022 09:20 pm ET
SHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Myovant Sciences Ltd. - MYOV
NEW YORK, Oct. 24, 2022 /PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Myovant Sciences Ltd. (MYOV), relating to its proposed acquisition by Sumitovant Bopharma Ltd. and Sumitomo Pharma Co., Ltd. Under the terms of the agreement, MYOV shareholders are expected to receive $27.00 in cash per share they own. Cl
Oct 24, 2022 05:17 pm ET
SHAREHOLDER ALERT: Weiss Law Investigates Myovant Sciences Ltd.
NEW YORK, Oct. 24, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Myovant Sciences Ltd. ("Myovant" or the "Company") (NYSE: MYOV) in connection with the proposed acquisition of the Company by Sumitovant Biopharma Ltd. and Sumitomo Pharma Co., Ltd. Under the terms of the merger agreement, the Company's shareholders will receive $27.00 in cash for each share of Myovant common stock owned. The transaction is valued at approximately $1.7 billion. 
Oct 24, 2022 04:30 pm ET
Myovant Sciences Cancels Second Quarter Earnings Conference Call
Myovant Sciences (NYSE: MYOV) (“Myovant”) today announced the cancellation of its earnings conference call for the quarter ended September 30, 2022 that had originally been scheduled for October 26, 2022 at 5:00 p.m. Eastern Time. The call is being...
Oct 24, 2022 08:31 am ET
Thinking about buying stock in Myovant Sciences, Sellas Life Sciences, Borr Drilling, Mullen Automotive, or Immunic?
NEW YORK, Oct. 24, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MYOV, SLS, BORR, MULN, and IMUX.
Oct 24, 2022 08:01 am ET
MYOV STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Myovant Sciences Ltd. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Myovant Sciences Ltd. (NYSE: MYOV) to Sumitovant Biopharma Ltd. for $27.00 per share in cash is fair to Myovant shareholders.
Oct 23, 2022 11:36 pm ET
Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive Agreement
Sumitovant Biopharma Ltd. (“Sumitovant”), in conjunction with parent company Sumitomo Pharma Co., Ltd. (“Sumitomo Pharma”), and Myovant Sciences (“Myovant”) (NYSE: MYOV) announced today that they have entered into a definitive agreement pursuant to...
Oct 23, 2022 11:30 pm ET
Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive Agreement
Sumitovant Biopharma to Acquire all Outstanding Shares of Myovant for $27 Per Share in Cash
Oct 18, 2022 04:30 pm ET
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced that it approved equity awards for 10...
Oct 14, 2022 10:02 am ET
CORRECTION -- Myovant Sciences, Inc.
In a release issued under the headline "Myovant Sciences to Host Second Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m." earlier today by Myovant Sciences, Inc. (NYSE: MYOV), please note that the date of the conference call was omitted...
Oct 14, 2022 06:45 am ET
Myovant Sciences to Host Second Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m.
Myovant Sciences (NYSE: MYOV), today announced it will host a webcast and conference call to discuss corporate updates and financial results for its second fiscal quarter, ended September 30, 2022. The webcast and conference call will be held at...
Oct 03, 2022 08:30 am ET
Thinking about buying stock in Myovant Sciences, Clovis Oncology, FingerMotion, LogicBio Therapeutics, or Amplify Energy?
NEW YORK, Oct. 3, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MYOV, CLVS, FNGR, LOGC, and AMPY.
Oct 02, 2022 07:36 pm ET
Myovant Sciences Special Committee of Board Confirms Receipt of Preliminary, Non-binding Proposal from Sumitovant Biopharma and Sumitomo Pharma to Acquire Remaining Shares
Myovant Sciences Ltd. (NYSE: MYOV) (the “Company”) confirmed today that it has received a preliminary, non-binding proposal (the “Proposal”) from Sumitovant Biopharma Ltd. (“Sumitovant”) and Sumitomo Pharma Co., Ltd. (collectively with Sumitovant,...
Sep 16, 2022 04:30 pm ET
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced that it approved equity awards for 7...
Sep 16, 2022 10:37 am ET
Myovant Recognizes Prostate Cancer Awareness Month with Educational Sponsorships and Online Campaign to Encourage Patients to Speak Up, Seek Support and Be Informed
Myovant Sciences (NYSE: MYOV) today announced an educational campaign to inspire prostate cancer patients to speak up and seek support through authentic conversations, along with the sponsorship of educational opportunities for patients, providers,...
Sep 02, 2022 06:45 am ET
Myovant Sciences to Participate at Upcoming Investor Conferences
Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced that David Marek, Chief Executive...
Aug 16, 2022 04:30 pm ET
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced that it approved equity awards for 11...
Aug 09, 2022 10:59 am ET
Thinking about buying stock in Bed Bath & Beyond, Helbiz, Myovant Sciences, BP, or Avaya?
NEW YORK, Aug. 9, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BBBY, HLBZ, MYOV, BP, and AVYA.
Aug 08, 2022 09:31 am ET
Thinking about buying stock in Iveda Solutions, Marathon Digital, Myovant Sciences, Benson Hill, or Quoin Pharmaceuticals?
NEW YORK, Aug. 8, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IVDA, MARA, MYOV, BHIL, and QNRX.
Aug 05, 2022 08:50 pm ET
Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis
Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved MYFEMBREE® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) as a one-pill, once-a-day therapy...
Jul 27, 2022 04:05 pm ET
Myovant Sciences Announces Corporate Updates and Financial Results for First Fiscal Quarter 2022
Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced financial results for the first...
Jul 18, 2022 04:30 pm ET
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced that it approved equity awards for 9...
Jul 13, 2022 06:45 am ET
Myovant Sciences to Host First Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m. Eastern Time on July 27, 2022
Myovant Sciences (NYSE: MYOV), today announced it will host a webcast and conference call to discuss corporate updates and financial results for its first fiscal quarter, ended June 30, 2022. The webcast and conference call will be held at 5:00...
Jun 27, 2022 08:00 am ET
Enzyvant Receives 2022 Rare Impact Industry Innovation Award from the National Organization for Rare Disorders (NORD) for Novel, Tissue-Based Therapy to Treat Ultra-Rare, Life-Threatening Pediatric Co
Enzyvant, a commercial-stage biotechnology company with a focus on regenerative medicines for rare diseases, announced today it is among the National Organization for Rare Disorders (NORD) 2022 Industry Innovation Awards recipients for the...
Jun 17, 2022 06:45 am ET
Myovant Sciences and Pfizer Announce Publication in The Lancet of Phase 3 SPIRIT 1 and SPIRIT 2 Studies of Once-Daily Relugolix Combination Therapy in Women With Endometriosis-Associated Pain
Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that results of the Phase 3 SPIRIT 1 and SPIRIT 2 studies of investigational once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone...
Jun 16, 2022 04:35 pm ET
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced that it approved equity awards for 23...
Jun 03, 2022 06:50 am ET
Myovant Sciences to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference
Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced that David Marek, Chief Executive...
Jun 02, 2022 06:50 am ET
Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE®
Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) accepted for review a supplemental New Drug Application (sNDA) for MYFEMBREE® (relugolix 40 mg, estradiol 1 mg, and...
May 16, 2022 09:00 am ET
Spirovant Launches State-of-the-Art Laboratory and Headquarters
The facilities are located in the center of Philadelphia's thriving life sciences corridor
May 10, 2022 08:00 am ET
Phathom Pharmaceuticals Reports First Quarter 2022 Results and Provides Recent Clinical, Regulatory, and Business Updates
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the first quarter of 2022 and provided updates...
May 10, 2022 06:55 am ET
Myovant Sciences Announces Corporate Updates and Financial Results for Fourth Fiscal Quarter and Fiscal Year Ended March 31, 2022
Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced financial results for the fourth...
May 09, 2022 06:30 am ET
Myovant Sciences and Accord Healthcare, Ltd. Enter into Exclusive License Agreement to Commercialize ORGOVYX® for Advanced Hormone-Sensitive Prostate Cancer in Europe
Myovant Sciences (NYSE: MYOV) and Accord Healthcare, Ltd. (Accord) today announced that they have entered into an exclusive license agreement for Accord to commercialize relugolix for the treatment of advanced hormone-sensitive prostate cancer...
May 06, 2022 08:00 am ET
ALTAVANT SCIENCES PRESENTS DATA SHOWING POTENTIAL FOR COMBINATION OF RODATRISTAT ETHYL AND AMBRISENTAN IN MODEL OF PULMONARY ARTERIAL HYPERTENSION
CARY, N.C. and BASEL, Switzerland, May 6, 2022 /PRNewswire/ -- Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, announced today that the company is presenting results from a preclinical study comparing rodatristat ethyl as a monotherapy and in combination with the type A endothelin receptor antagonist, ambrisentan, in an animal model of pulmonary arterial hypertension (PAH). Results describing changes in post-hypoxia occlusions as well as mean pulmonary arterial pressure (mPAP) with each treatment regimen
May 06, 2022 06:45 am ET
Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application (sNDA) for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis
Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for MYFEMBREE® (relugolix 40 mg, estradiol 1...
May 02, 2022 08:00 am ET
ALTAVANT SCIENCES PRESENTED DATA AT ISHLT SHOWING POTENCY AND DISTRIBUTION OF BRONCHIOLITIS OBLITERANS CANDIDATE, ALTA-2530
CARY, N.C., and BASEL, Switzerland, May 2, 2022 /PRNewswire/ -- Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, announced today that the company made an oral presentation of preclinical results supporting the development of ALTA-2530 for the treatment of bronchiolitis obliterans syndrome (BOS) at the International Society for Heart & Lung Transplantation (ISHLT) annual meeting in Boston, MA. ALTA-2530, an inhaled formulation of a human IL-1 receptor antagonist (IL-1Ra), is in development at Altavant f
Apr 29, 2022 07:10 pm ET
Myovant Sciences Announces European Commission Approval for ORGOVYX® (relugolix) for the Treatment of Advanced Hormone-Sensitive Prostate Cancer
Myovant Sciences (NYSE: MYOV) today announced that the European Commission (EC) has approved the marketing authorisation application for ORGOVYX® (relugolix, 120 mg) for the treatment of adult patients with advanced hormone-sensitive prostate...
Apr 26, 2022 08:30 am ET
Myovant Sciences to Host Fourth Fiscal Quarter and Fiscal Year 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on May 10, 2022
Myovant Sciences (NYSE: MYOV) today announced it will host a webcast and conference call to discuss corporate updates and financial results for its fourth fiscal quarter and fiscal year 2021, ended March 31, 2022. The webcast and conference call...
Apr 26, 2022 08:00 am ET
Phathom Pharmaceuticals Appoints Frank Karbe to its Board of Directors
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Frank Karbe to its Board of Directors. Mr. Karbe,...
Apr 21, 2022 08:00 am ET
Enzyvant Announces Plans to Expand Regenerative Medicine Manufacturing Capabilities
Enzyvant, a commercial-stage biotechnology company with a focus on regenerative medicines for rare diseases, announced today plans to develop a Good Manufacturing Practice (GMP)-compliant regenerative medicine manufacturing facility in Morrisville,...
Apr 12, 2022 12:00 am ET
Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated with Endometriosis
Myovant Sciences (NYSE: MYOV) and Pfizer (NYSE: PFE) announced today an update on the Supplemental New Drug Application (sNDA) for MYFEMBREE® (relugolix 40 mg, estradiol 1 mg and norethindrone acetate 0.5 mg) for the management of moderate to...
Feb 25, 2022 09:00 am ET
Myovant Sciences Receives Positive CHMP Opinion for ORGOVYX® (relugolix) for the Treatment of Advanced Prostate Cancer
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion...
Feb 10, 2022 08:00 am ET
Sumitomo Dainippon Pharma and Sumitovant Biopharma Initiate Phase 1 Study on New Drug Candidate for Carbapenem-Resistant Bacterial Infections
LONDON and NEW YORK, Feb. 10, 2022 /PRNewswire/ -- Sumitovant Biopharma Ltd., in partnership with its parent company Sumitomo Dainippon Pharma Co., Ltd., recently announced the launch of a phase 1 study in the U.S. on a new drug candidate ("KSP-1007") for carbapenem-resistant bacterial infections. The launch is a result of a joint research project between Sumitomo Dainippon Pharma and the Kitasato Institute in Japan. Sumitovant is leading the program of the compound in the U.S. targeting complicated urinary tract and intra-abdominal infections.
Feb 07, 2022 08:30 am ET
Myovant Sciences to Present at Upcoming Investor Conferences
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that David Marek, Chief Executive Officer of Myovant Sciences, Inc., and other members of the Myovant executive team will...
Jan 26, 2022 08:00 am ET
Enzyvant Appoints Johanna Rossell as Chief Commercial Officer
Enzyvant today announced the appointment of Johanna Rossell as Chief Commercial Officer. Johanna Rossell has an extensive background in the pharmaceutical and healthcare sector, leading multifunctional teams across several geographic markets...
Jan 26, 2022 06:55 am ET
Myovant Sciences Announces Financial Results for Third Quarter of Fiscal Year 2021 and Corporate Updates
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced financial results for the third quarter of fiscal year 2021 and other corporate updates. “Our third fiscal quarter 2021 financial...
Jan 12, 2022 08:30 am ET
Myovant Sciences to Host Third Fiscal Quarter 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on January 26, 2022
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and conference call to discuss corporate updates and financial results for its third fiscal quarter 2021,...
Jan 10, 2022 06:55 am ET
Myovant Sciences Announces Preliminary Financial Results for Third Quarter of Fiscal Year 2021
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced preliminary financial results for the third quarter of fiscal year 2021. The financial information presented in this press release...
Jan 03, 2022 08:30 am ET
Myovant Sciences to Present at the 40th Annual J.P. Morgan Healthcare Conference
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that David Marek, Chief Executive Officer of Myovant Sciences, Inc., will present at the 40th Annual J.P. Morgan Healthcare...
Dec 10, 2021 09:26 am ET
Sumitovant Biopharma Highlights Significant Clinical, Regulatory and Commercial Achievements Across its Portfolio of Companies in the Second Quarter of FY2021
LONDON and NEW YORK, Dec. 10, 2021 /PRNewswire/ -- Sumitovant Biopharma, Inc. today announced that its portfolio of four wholly-owned subsidiary companies (Urovant, Enzyvant, Altavant and Spirovant) and Myovant (NYSE: MYOV), a publicly listed company that is majority-owned by Sumitovant, achieved significant clinical, regulatory and commercial milestones during the company's second quarter of fiscal year 2021 ending in October.
Nov 23, 2021 08:30 am ET
Myovant Sciences to Participate in the Evercore ISI 4th Annual HealthCONx Conference
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, will participate in the Evercore ISI 4th Annual HealthCONx Conference on November 30, 2021. David Marek, Chief Executive Officer of Myovant...
Nov 08, 2021 06:00 am ET
Nancy Valente, M.D. Joins Myovant Sciences’ Board of Directors
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the appointment of Nancy Valente, M.D. as an independent member of the company’s Board of Directors. Dr. Valente is a renowned...
Oct 28, 2021 12:03 pm ET
Spirovant to Present SP-101 Data at the 2021 North American Cystic Fibrosis Conference
PHILADELPHIA, Oct. 28, 2021 /PRNewswire/ -- Spirovant Sciences, a gene therapy company developing treatments and cures for inherited respiratory diseases including cystic fibrosis (CF), today announced that it will be delivering oral and poster presentations highlighting pre-clinical data for its compound, SP-101, at the 2021 North American Cystic Fibrosis Conference (NACFC 2021), November 2-5. SP-101, an investigational novel recombinant adeno-associated virus (AAV) gene therapy selected for its tropism to human airway epithelia, is being developed for inhalation in patients with CF who do
Oct 26, 2021 06:55 am ET
Myovant Sciences Announces Financial Results for Second Quarter of Fiscal Year 2021 and Corporate Updates
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced financial results for the second quarter of fiscal year 2021 and other corporate updates. “During our second fiscal quarter, we...
Oct 19, 2021 06:58 am ET
Myovant Sciences and Pfizer Present Data on Relugolix Combination Therapy from Studies in Uterine Fibroids and Endometriosis at the American Society for Reproductive Medicine Congress
Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced the presentation of new data from clinical studies of its once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in...
Oct 12, 2021 08:30 am ET
Myovant Sciences to Host Second Fiscal Quarter 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on October 26, 2021
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and conference call to discuss corporate updates and financial results for its second fiscal quarter 2021,...
Oct 08, 2021 08:09 pm ET
Enzyvant Receives FDA Approval for RETHYMIC® (allogeneic processed thymus tissue-agdc), a One-Time Regenerative Tissue-Based Therapy for Pediatric Congenital Athymia
Enzyvant today announced the U.S. Food and Drug Administration (FDA) approval of RETHYMIC® (allogeneic processed thymus tissue-agdc), a one-time regenerative tissue-based therapy for immune reconstitution in pediatric patients with congenital...
Sep 09, 2021 06:58 am ET
Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis
Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for review a supplemental New Drug Application (sNDA) for MYFEMBREE® (relugolix 40 mg, estradiol 1 mg, and...
Sep 01, 2021 08:30 am ET
Myovant Sciences to Participate in the 2021 Baird Global Healthcare Conference
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, will participate in the 2021 Baird Global Healthcare Conference on September 15, 2021. Company management will participate in a fireside chat at...
Aug 26, 2021 09:00 am ET
Enzyvant Announces First-Ever Data on Burden of Illness and Costs of Supportive Care for Pediatric Congenital Athymia
Data from two first-ever studies reveal extreme clinical, emotional, social, and financial burdens on patients with pediatric congenital athymia and their families, and extraordinary costs of supportive care to healthcare systems. Congenital...
Aug 12, 2021 04:01 pm ET
Myovant Sciences Appoints Uneek Mehra as Chief Financial and Business Officer
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and men, today announced the appointment of Uneek Mehra as Chief Financial and Business Officer of Myovant Sciences, Inc.  Mr. Mehra will succeed Frank Karbe,...
Aug 04, 2021 09:49 am ET
Enzyvant Announces Publication of Positive Clinical Data in Pediatric Patients with Congenital Athymia Treated with Investigational RVT-802 (allogeneic processed thymus tissue-agdc)
Kaplan-Meier estimated survival at one year and two years post treatment with investigational RVT-802 was 77% and 76%, respectively Follow-up time in the Efficacy Analysis Set (EAS) ranged from 0 to 25.5 years; For patients who were alive at one...
Jul 28, 2021 06:55 am ET
Myovant Sciences Announces Financial Results for First Quarter of Fiscal Year 2021 and Corporate Updates
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced corporate updates and financial results for the first quarter of fiscal year 2021. “I am pleased with the significant progress...
Jul 20, 2021 02:00 am ET
Myovant Sciences Announces European Commission Approval for RYEQO® for the Treatment of Women With Uterine Fibroids
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the European Commission (EC) has approved the marketing authorization application for RYEQO® (relugolix 40 mg, estradiol 1.0 mg,...
Jul 14, 2021 08:30 am ET
Myovant Sciences to Host First Fiscal Quarter 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on July 28, 2021
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and conference call to discuss corporate updates and financial results for its first fiscal quarter 2021,...
Jun 01, 2021 08:30 am ET
Myovant Sciences to Present at Upcoming Investor Conferences
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, invites investors and the general public to listen to webcasts at the following investor conferences: Goldman Sachs 42nd Annual Global Healthcare...
May 26, 2021 04:15 pm ET
Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE®, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids
Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved MYFEMBREE® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg), the first once-daily treatment...
May 21, 2021 08:30 am ET
Myovant Sciences Receives Positive CHMP Opinion for RYEQO® (Relugolix Combination Tablet) for the Treatment of Women With Uterine Fibroids
Myovant Sciences (NYSE: MYOV) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending the approval of RYEQO® (relugolix 40 mg, estradiol 1.0 mg, and...
May 11, 2021 06:58 am ET
Myovant Sciences Announces Corporate Updates and Financial Results for Fourth Fiscal Quarter and Fiscal Year Ended March 31, 2021
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced corporate updates and financial results for the fourth fiscal quarter and fiscal year ended March 31, 2021. “The ORGOVYX launch...
May 04, 2021 08:30 am ET
Myovant Sciences to Host Fourth Fiscal Quarter and Fiscal Year 2020 Earnings Conference Call at 8:30 a.m. Eastern Time on May 11, 2021
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and conference call to discuss corporate updates and financial results for its fourth fiscal quarter and...
Apr 12, 2021 06:58 am ET
Myovant Sciences and Pfizer Announce First Participant Dosed in Phase 3 SERENE Study Evaluating Contraceptive Efficacy of Once-Daily Relugolix Combination Tablet
Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in the Phase 3 SERENE study evaluating the contraceptive efficacy of relugolix combination tablet (relugolix 40 mg, estradiol 1.0...
Apr 05, 2021 06:58 am ET
Myovant Sciences Appoints Lauren Merendino as Chief Commercial Officer
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the appointment of Lauren Merendino as Chief Commercial Officer of Myovant Sciences, Inc., effective April 5, 2021. Ms. Merendino...
Mar 29, 2021 06:58 am ET
Myovant Sciences Announces European Medicines Agency Validation of Marketing Authorization Application for Relugolix for the Treatment of Advanced Prostate Cancer
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for relugolix for the treatment of...
Mar 24, 2021 06:30 am ET
Myovant Sciences and Pfizer Announce Positive Data from Phase 3 LIBERTY Randomized Withdrawal Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced positive data from the Phase 3 LIBERTY randomized withdrawal study of relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg)...
Mar 23, 2021 08:30 am ET
Myovant Sciences Announces Recipients of “Forward for Health Equity” Grants to Improve Healthcare Access in Prostate Cancer and Uterine Fibroids
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the four recipients of its Forward for Health Equity grants. The grant program provides funding to nonprofit healthcare...
Feb 22, 2021 08:30 am ET
Myovant Sciences to Present at Upcoming Investor Conferences
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, invites investors and the general public to listen to webcasts at the following investor conferences: SVB Leerink 10th Annual Global Healthcare...
Feb 17, 2021 05:02 pm ET
Myovant Sciences and Pfizer Announce Publication in the New England Journal of Medicine of Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced publication in the New England Journal of Medicine of the Phase 3 LIBERTY 1 and LIBERTY 2 studies of investigational once-daily relugolix combination therapy (relugolix 40 mg...
Feb 17, 2021 08:30 am ET
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that it approved equity awards for 7 new employees with a grant date of February 16, 2021 pursuant to Myovant’s 2020 Inducement...
Feb 16, 2021 08:32 am ET
HealthyWomen and Myovant Sciences Launch “Voices of Periods” to Fight Menstrual Stigma
HealthyWomen, the nation’s leading independent, nonprofit health information source for women, and Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today launched “Voices of Periods,” a...
Feb 11, 2021 06:55 am ET
Myovant Sciences Announces Corporate Updates and Financial Results for Third Quarter of Fiscal Year 2020
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced corporate updates and financial results for the third quarter of fiscal year 2020. “The FDA approval of ORGOVYX and the landmark...
Jan 29, 2021 08:30 am ET
Myovant Sciences to Host Third Fiscal Quarter 2020 Earnings Conference Call at 8:30 a.m. Eastern Time on February 11, 2021
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and conference call to discuss corporate updates and financial results for its third fiscal quarter 2020,...
Jan 26, 2021 06:55 am ET
Myovant Sciences and Pfizer Announce Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis
Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the Phase 3 SPIRIT long-term extension study of the investigational once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone...
Jan 20, 2021 08:30 am ET
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that it approved equity awards to David Marek in connection with his previously-announced employment by Myovant Sciences, Inc....
Jan 05, 2021 08:30 am ET
Myovant Sciences to Present at the 39th Annual J.P. Morgan Healthcare Conference
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that David Marek, chief executive officer of Myovant Sciences, Inc., will present at the virtual 39th Annual J.P. Morgan...
Jan 05, 2021 06:58 am ET
Myovant Sciences Announces U.S. Availability of ORGOVYX™ for the Treatment of Advanced Prostate Cancer
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that ORGOVYX™ (relugolix), the first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonist approved by the U.S....
Jan 04, 2021 06:58 am ET
Myovant Sciences Appoints Industry Veteran David Marek as Chief Executive Officer
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the appointment of David Marek as chief executive officer of Myovant Sciences, Inc. Mr. Marek will also serve as principal...
Dec 28, 2020 07:30 am ET
Thinking about buying stock in Ocugen, Marathon, Phunware, Myovant Sciences, or Gevo?
NEW YORK, Dec. 28, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OCGN, MARA, PHUN, MYOV, and GEVO.
Dec 28, 2020 06:30 am ET
Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women’s Health
Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced a collaboration to develop and commercialize relugolix – a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist – in oncology and women’s health in the...
Dec 18, 2020 04:49 pm ET
Myovant Sciences Announces FDA Approval of ORGOVYX™ (relugolix), the First and Only Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer
ORGOVYX demonstrated a 96.7% response rate in testosterone suppression to castrate levels ( 280 ng/dL) or returned to baseline within 90 days of treatment discontinuation. The most frequent adverse events reported in at least 10% of men in the...
Dec 17, 2020 08:31 am ET
Thinking about buying stock in MacroGenics, Arbutus Biopharma, Riot Blockchain, Aclaris Therapeutics, or Myovant Sciences?
NEW YORK, Dec. 17, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MGNX, ABUS, RIOT, ACRS, and MYOV.
Dec 16, 2020 08:30 am ET
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that it approved equity awards for 46 new employees with a grant date of December 15, 2020 pursuant to Myovant’s 2020 Inducement...
Nov 23, 2020 07:00 am ET
Myovant Sciences to Present at Upcoming December Investor Conferences
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, invites investors and the general public to listen to webcasts at the following investor conferences: Evercore ISI 3rd Annual HealthCONx Virtual...
Nov 17, 2020 08:30 am ET
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that it approved equity awards for 72 new employees with a grant date of November 15, 2020 pursuant to Myovant’s 2020...
Nov 13, 2020 08:31 am ET
Thinking about buying stock in Zomedica Corp, Niu Technologies, Aurora Cannabis, Myovant Sciences, or Boxlight Corp?
NEW YORK, Nov. 13, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ZOM, NIU, ACB, MYOV, and BOXL.
Nov 12, 2020 07:00 am ET
Myovant Sciences Announces Corporate Updates and Financial Results for Second Quarter Fiscal Year 2020
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced corporate updates and financial results for the second quarter fiscal year 2020. “I am very pleased with the significant progress...
Nov 02, 2020 08:30 am ET
Myovant Sciences to Host Second Fiscal Quarter 2020 Earnings Conference Call at 8:30 a.m. Eastern Time on November 12, 2020
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and conference call to discuss corporate updates and financial results for its second fiscal quarter 2020,...
Oct 21, 2020 08:30 am ET
Myovant Sciences Presents Additional Data on Relugolix Combination Therapy from Studies in Endometriosis and Uterine Fibroids
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the presentation of data from clinical studies of its once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0...
Oct 14, 2020 08:30 am ET
Myovant Sciences Appoints Ryan Crowe as Vice President, Investor Relations
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the appointment of Ryan Crowe as vice president, investor relations. In addition to managing day-to-day interactions with analysts...
Sep 29, 2020 08:30 am ET
Myovant Sciences Announces Results of Additional Secondary Endpoint of Castration Resistance-Free Survival from Phase 3 HERO Study of Relugolix in Advanced Prostate Cancer
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced results of an additional secondary endpoint from the Phase 3 HERO study evaluating relugolix in men with advanced prostate cancer....
Sep 23, 2020 08:30 am ET
Myovant Sciences Launches “Forward for Health Equity” Grant Program to Improve Healthcare Access in Prostate Cancer and Uterine Fibroids
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the launch of its “Forward for Health Equity” grant program. The program will provide funding to nonprofit healthcare...
Sep 14, 2020 08:30 am ET
Myovant Sciences Presents Additional Data on Bone Mineral Density in Women with Uterine Fibroids from Phase 3 LIBERTY Program and from Prospective Observational Study
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the presentation of one-year data on bone mineral density (BMD) from the Phase 3 LIBERTY program evaluating the safety and...
Aug 17, 2020 08:30 am ET
Myovant Sciences Announces FDA Acceptance of New Drug Application for Once-Daily Relugolix Combination Tablet for Uterine Fibroids
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that its New Drug Application (NDA) for once-daily, oral relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and...
Aug 11, 2020 08:30 am ET
Myovant Sciences Announces Corporate Updates and Financial Results for First Quarter Fiscal Year 2020
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced corporate updates and financial results for the first quarter fiscal year 2020. "I am very proud of the many recent...
Aug 05, 2020 08:30 am ET
Myovant Sciences Announces Further Financing Support from Sumitomo Dainippon Pharma and Commercial Collaboration with Sunovion Pharmaceuticals
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced a USD 200 million low-interest, five-year term loan commitment from Sumitomo Dainippon Pharma Co., Ltd. (TSE: 4506), bringing its...
Jul 06, 2020 08:30 am ET
Myovant Sciences Presents Additional Data on Relugolix Combination Therapy from Phase 3 LIBERTY Studies in Women with Uterine Fibroids and from Ovulation Inhibition Study
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the presentation of additional data from clinical studies of its once-daily relugolix combination therapy (relugolix 40 mg plus...
Jun 30, 2020 08:30 am ET
BlackDoctor.org, Evidation Health, Movember, and Myovant Sciences Launch Forward Momentum Coalition to Increase Diversity in Research and Develop New Digital Resources for Men with Prostate Cancer
BlackDoctor.org, Evidation Health, Movember, and Myovant Sciences (NYSE: MYOV) today announced the launch of Forward Momentum, a cross-sector coalition working on innovative projects to increase diversity in research and develop new digital...
Jun 23, 2020 09:31 am ET
Thinking about trading options or stock in Fastly Inc, Myovant Sciences, Tesla, Spotify, or MGM Resorts?
NEW YORK, June 23, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FSLY, MYOV, TSLA, SPOT, and MGM.
Jun 23, 2020 07:30 am ET
Myovant Sciences Announces Positive Results from Second Phase 3 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Endometriosis
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced top-line results from SPIRIT 1, the second of two Phase 3 studies of once-daily relugolix combination therapy (relugolix 40 mg...
Jun 22, 2020 10:14 pm ET
Sumitovant Biopharma Announces Priority Review and FDA Acceptance of Myovant Sciences New Drug Application for Once-Daily, Oral Relugolix for Advanced Prostate Cancer
Sumitovant Biopharma is pleased to announce that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review, the New Drug Application (NDA) submitted by Myovant Sciences (NYSE: MYOV), for once-daily, oral relugolix (120 mg) for...
Jun 22, 2020 04:05 pm ET
Myovant Sciences to Host Webcast and Conference Call at 8:30 am Eastern Time Tuesday, June 23 to Discuss Results from Phase 3 SPIRIT 1 Study Evaluating Once-Daily Relugolix Combination Therapy in Wome
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that it will host a webcast and conference call to discuss top-line results from the Phase 3 SPIRIT 1 study of once-daily...
Jun 22, 2020 08:30 am ET
Myovant Sciences Announces Priority Review and FDA Acceptance of New Drug Application for Once-Daily, Oral Relugolix for Advanced Prostate Cancer
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that its New Drug Application (NDA) for once-daily, oral relugolix (120 mg) for the treatment of men with advanced prostate cancer...
Jun 01, 2020 05:11 pm ET
Sumitovant Biopharma Announces Myovant Sciences' Submission of New Drug Application (NDA) to the FDA for Once-Daily Relugolix Combination Tablet for the Treatment of Women with Uterine Fibroids
NEW YORK and LONDON, June 1, 2020 /PRNewswire/ -- Sumitovant Biopharma Ltd. announced today that Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, and one of five healthcare companies in the Sumitovant family of companies, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its once-daily relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) for the treatment of women with heavy menstrual bleeding associated with uterine fibroids.
Jun 01, 2020 08:00 am ET
Myovant Sciences Submits New Drug Application (NDA) to the FDA for Once-Daily Relugolix Combination Tablet for the Treatment of Women with Uterine Fibroids
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its once-daily relugolix...
May 29, 2020 05:00 pm ET
Sumitovant Biopharma Announces Myovant Sciences' Additional Positive Efficacy and Cardiovascular Safety Data from Phase 3 HERO Study of Once-Daily, Oral Relugolix in Advanced Prostate Cancer and Publi
LONDON and NEW YORK, May 29, 2020 /PRNewswire/ -- Sumitovant Biopharma Ltd. announced that Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, and one of five healthcare companies in the Sumitovant family of companies, today had additional results from its Phase 3 HERO study of once-daily, oral relugolix (120 mg) in men with advanced prostate cancer presented orally at the American Society of Clinical Oncology (ASCO)'s ASCO20 Virtual Scientific Program and simultaneously published in the New England Journal of Medicine (NEJM). The data expand
May 29, 2020 08:09 am ET
Myovant Sciences Announces Additional Positive Efficacy and Cardiovascular Safety Data from Phase 3 HERO Study of Once-Daily, Oral Relugolix in Advanced Prostate Cancer and Publication in the New Engl
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced additional results from its Phase 3 HERO study of once-daily, oral relugolix (120 mg) in men with advanced prostate cancer in an...
May 18, 2020 04:05 pm ET
Myovant Sciences Provides Recent Corporate Updates and Reports Financial Results for Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2020
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced recent corporate updates and reported financial results for the fourth fiscal quarter and full fiscal year ended March 31, 2020....
May 14, 2020 08:30 am ET
Myovant Sciences to Present New Data on Relugolix in Prostate Cancer at American Society of Clinical Oncology (ASCO) 2020 Annual Meeting
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that it will present new efficacy and cardiovascular safety data from the Phase 3 HERO study of once-daily, oral relugolix (120...
Apr 27, 2020 08:30 am ET
Myovant Sciences Announces Publication of Abstracts Detailing Additional Efficacy and Safety Findings from Phase 3 LIBERTY Studies in Uterine Fibroids in Obstetrics & Gynecology
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women’s health and prostate cancer, today announced that the journal Obstetrics & Gynecology has published three abstracts detailing additional efficacy and safety...
Apr 22, 2020 07:30 am ET
Myovant Sciences Announces Positive Results from Phase 3 SPIRIT 2 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Endometriosis and from Ovulation Inhibition Study
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women's health and prostate cancer, today announced that SPIRIT 2, the first of two Phase 3 studies of once-daily relugolix combination therapy (relugolix 40 mg plus...
Apr 21, 2020 04:05 pm ET
Myovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Wednesday, April 22 to Discuss Results from Phase 3 SPIRIT 2 Study Evaluating Once-Daily Relugolix Combination Therapy in
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women's health and prostate cancer, today announced it will hold a webcast and conference call beginning at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time on...
Apr 21, 2020 08:30 am ET
Myovant Sciences Submits New Drug Application (NDA) to the FDA for Once-Daily, Oral Relugolix for the Treatment of Men with Advanced Prostate Cancer
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women's health and prostate cancer, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for once-daily,...
Apr 14, 2020 08:30 am ET
Myovant Sciences and HealthyWomen Launch Storytelling Initiative to Elevate Conversations About Menstrual Health
Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, and HealthyWomen, the nation’s leading independent, nonprofit health information source for women, today...
Mar 31, 2020 09:31 am ET
Thinking about buying stock in American Airlines, Aurora Cannabis, CommVault Systems, Myovant Sciences, or Penn National Gaming?
NEW YORK, March 31, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAL, ACB, CVLT, MYOV, and PENN.
Mar 31, 2020 02:00 am ET
Myovant Sciences and Gedeon Richter Enter into Exclusive License Agreement to Commercialize Relugolix Combination Tablet for Uterine Fibroids and Endometriosis in Certain Territories Outside the U.S.
Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, and Gedeon Richter Plc., a major pharmaceutical company in Central Eastern Europe focused on women’s health,...
Mar 10, 2020 08:30 am ET
Myovant Sciences Announces Cancellation of Presentation and Webcast at the Barclays Global Healthcare Conference 2020
Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, today announced the cancellation of its presentation and webcast at the Barclays Global Healthcare Conference,...
Mar 09, 2020 08:30 am ET
Myovant Sciences Submits Marketing Authorization Application to the European Medicines Agency for Relugolix Combination Tablet for the Treatment of Women with Uterine Fibroids
Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency...
Feb 25, 2020 08:30 am ET
Myovant Sciences to Present at Upcoming March Investor Conferences
Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, today announced that Lynn Seely, M.D., Myovant’s CEO, will present at the following investor conferences:...
Feb 10, 2020 08:30 am ET
Myovant Sciences Provides Recent Corporate Updates and Reports Financial Results for Third Fiscal Quarter Ended December 31, 2019
Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women’s health and prostate cancer, today announced recent corporate updates and reported financial results for the third fiscal quarter ended...
Feb 10, 2020 08:25 am ET
Myovant Sciences Announces 88% One-Year Response Rate in Positive Phase 3 LIBERTY Extension Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, today announced that the Phase 3 LIBERTY open-label extension study of once-daily, oral relugolix combination...
Jan 06, 2020 08:30 am ET
Myovant Sciences to Present at the 38th Annual J.P. Morgan Healthcare Conference
Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, today announced that Lynn Seely, M.D., Myovant’s CEO, will present at the 38th Annual J.P. Morgan Healthcare...
Dec 30, 2019 08:30 am ET
Myovant Sciences Announces Closing of $400 Million Loan Facility, Repayment of Debt, Board of Director Transitions, and Executive Promotions
Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, today announced the closing of the previously announced landmark, low-interest (3-month LIBOR plus 3%) loan...
Nov 25, 2019 04:05 pm ET
Myovant Sciences to Present at the Evercore ISI 2nd Annual HealthCONx Conference on December 3, 2019
Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, today announced that Lynn Seely, M.D., Myovant’s President and CEO, will present at the Evercore ISI 2nd Annual...
Nov 19, 2019 07:30 am ET
Myovant Sciences Announces 97% Response Rate in Positive Phase 3 HERO Study of Once-Daily, Oral Relugolix in Men with Advanced Prostate Cancer
Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, today announced that the Phase 3 HERO study of once-daily, oral relugolix (120 mg) met its primary efficacy...
Nov 18, 2019 04:05 pm ET
Myovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Tuesday, November 19 to Discuss Results from Phase 3 Study Evaluating Once-Daily, Oral Relugolix in Men with Advanced Pro
Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, today announced it will hold a webcast and conference call beginning at 8:30 a.m. Eastern Time / 5:30 a.m....
Nov 12, 2019 08:20 am ET
Myovant Sciences Provides Recent Corporate Updates and Reports Financial Results for Second Fiscal Quarter Ended September 30, 2019
Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women’s health and prostate cancer, today announced recent corporate updates and reported financial results for the second fiscal quarter ended...
Oct 31, 2019 09:20 am ET
Myovant Sciences Enters Landmark Agreement with Sumitomo Dainippon Pharma to Secure Major Financial Backing and Safeguards for Minority Shareholders
Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, today announced that it has entered into a landmark agreement with Sumitomo Dainippon Pharma Co., Ltd. (TSE:...
Oct 21, 2019 08:30 am ET
Myovant Sciences Completes Patient Recruitment for Phase 3 SPIRIT 1 Study Evaluating Relugolix Combination Therapy in Women with Endometriosis
Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, today announced that it has completed patient recruitment for its SPIRIT 1 study, the second of two Phase 3...
Oct 17, 2019 05:00 am ET
Female Forward Together, a Cross-Sector Coalition, Announced to Advance Research, Education, and Action for Women’s Health
Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, announced today the formation of Female Forward Together, a cross-sector coalition bringing together expertise...
Oct 17, 2019 05:00 am ET
First-of-Its-Kind Nationwide Survey from Myovant Sciences and Evidation Health Captures Impact of Menstrual Stigma and Symptoms
Pervasive stigma and prevalent symptoms related to menstruation are among the key takeaways from a new survey conducted by Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and...
Oct 10, 2019 08:30 am ET
Myovant Sciences Announces Late-Breaking Oral Presentation of Phase 3 LIBERTY 1 & 2 Study Results at 2019 American Society for Reproductive Medicine Scientific Congress
Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, today announced that results from its Phase 3 LIBERTY 1 & 2 studies of relugolix combination therapy in women...
Sep 06, 2019 03:01 am ET
Myovant Sciences’ Founding Shareholder Roivant Sciences, and Sumitomo Dainippon Pharma Enter into a Memorandum of Understanding to Create a Broad Strategic Alliance
Myovant Sciences (NYSE: MYOV) today announced that its founding shareholder, Roivant Sciences, and Sumitomo Dainippon Pharma Co., Ltd. (TSE: 4506) (“Sumitomo Dainippon”), a leading global Japanese pharmaceutical company, have announced their entry...
Aug 27, 2019 08:30 am ET
Myovant Sciences to Participate in Upcoming September Investor Conferences
Myovant Sciences (NYSE: MYOV), a clinical-stage healthcare company focused on developing and commercializing innovative therapies for women’s health and prostate cancer, today announced its participation in the following upcoming investor...
Aug 20, 2019 08:30 am ET
Myovant Sciences Completes Patient Recruitment for Phase 3 SPIRIT 2 Study Evaluating Relugolix Combination Therapy in Women with Endometriosis
Myovant Sciences (NYSE: MYOV), a clinical-stage healthcare company focused on developing and commercializing innovative therapies for women’s health and prostate cancer, today announced that it has completed patient recruitment for its SPIRIT 2...
Aug 06, 2019 04:05 pm ET
Myovant Sciences Provides Recent Corporate Updates and Reports Financial Results for First Fiscal Quarter Ended June 30, 2019
Myovant Sciences (NYSE: MYOV), a clinical-stage healthcare company focused on developing and commercializing innovative therapies for women’s health and prostate cancer, today announced recent corporate updates and reported financial results for...
Jul 23, 2019 07:30 am ET
Myovant Sciences Announces Positive Results from Second Phase 3 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids and Positive Results from Bioequivalence Study
Myovant Sciences (NYSE: MYOV), a clinical-stage healthcare company focused on developing and commercializing innovative therapies for women’s health and prostate cancer, today announced that LIBERTY 2, the second of two Phase 3 studies of...
Jul 22, 2019 04:01 pm ET
Myovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Tuesday, July 23rd to Discuss Results from Second Phase 3 Study Evaluating Once-Daily Relugolix Combination Therapy in Wo
Myovant Sciences (NYSE:MYOV), a clinical-stage healthcare company focused on developing and commercializing innovative therapies for women’s health and prostate cancer, today announced it will hold a webcast and conference call beginning at 8:30...
Jul 10, 2019 08:30 am ET
Myovant Sciences and Evidation Health Announce Partnership and Launch Digital Insights Study on Menstruation
Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, and Evidation Health, a health and measurement company that helps life sciences and healthcare companies...
Jun 04, 2019 08:30 am ET
Myovant Sciences to Present at Upcoming June Investor Conferences
Myovant Sciences (NYSE: MYOV), a clinical-stage healthcare company focused on developing and commercializing innovative therapies for women’s health and prostate cancer, today announced that Lynn Seely, M.D., President and Chief Executive Officer,...
May 30, 2019 09:01 pm ET
Myovant Sciences Announces Pricing of $125 Million Public Offering of Common Shares
Myovant Sciences (NYSE: MYOV) (“Myovant”), a clinical-stage healthcare company focused on developing and commercializing innovative therapies for women’s health and prostate cancer, today announced the pricing of its underwritten public offering of...
May 29, 2019 04:16 pm ET
Myovant Sciences Announces $100 Million Public Offering of Common Shares
Myovant Sciences (NYSE: MYOV) (“Myovant”), a clinical-stage healthcare company focused on developing and commercializing innovative therapies for women’s health and prostate cancer, today announced that it has commenced an underwritten public...
May 24, 2019 04:05 pm ET
Myovant Sciences Provides Corporate Updates and Reports Financial Results for Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2019
Myovant Sciences (NYSE: MYOV), a clinical-stage healthcare company focused on developing and commercializing innovative therapies for women’s health and prostate cancer, today announced corporate updates and reported financial results for the...
May 14, 2019 07:30 am ET
Myovant Sciences Announces Positive Phase 3 Results from LIBERTY 1 Study Evaluating Once Daily Relugolix Combination Therapy in Women with Uterine Fibroids
Bone mineral density maintained at levels comparable to placebo- Conference call and webcast to be held today at 8:30 a.m. EDT / 5:30 a.m. PDT BASEL, Switzerland, May 14, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a...
May 13, 2019 04:16 pm ET
Myovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Tuesday, May 14th to Discuss Results from Phase 3 LIBERTY 1 Study Evaluating Once Daily Relugolix Combination Therapy in
Myovant Sciences (NYSE:MYOV), a clinical-stage healthcare company focused on developing and commercializing innovative therapies for women’s health and prostate cancer, today announced it will hold a webcast and conference call beginning at 8:30...
Apr 17, 2019 07:15 am ET
New Research: Key Drivers of Growth for Rosetta Stone, Theravance Biopharma, Nexa Resources S.A, Barnes & Noble Education, LightInTheBox Holding Co., and Myovant Sciences — Factors of Influence, Major
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Rosetta Stone (NYSE:RST), Theravance Biopharma, Inc. (NASDAQ:TBPH), Nexa...
Mar 05, 2019 07:30 am ET
Myovant Sciences to Present at Upcoming Investor Conferences
BASEL, Switzerland, March 5, 2019 /PRNewswire/ -- Myovant Sciences (NYSE: MYOV), a leading clinical-stage biopharmaceutical company focused on women's health and endocrine diseases, today announced that Lynn Seely, M.D., President and Chief Executive Officer, will present at the following investor conferences:  
Feb 07, 2019 03:05 pm ET
Myovant Provides Corporate Updates and Reports Financial Results for Third Fiscal Quarter Ended December 31, 2018
BASEL, Switzerland, Feb. 7, 2019 /PRNewswire/ -- Myovant Sciences (NYSE: MYOV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of women's health and endocrine diseases, today announced corporate updates and reported financial results for the third fiscal quarter ended December 31, 2018.
Jan 02, 2019 07:00 am ET
Roivant Sciences to Present at the 37th Annual J.P. Morgan Healthcare Conference
NEW YORK and BASEL, Switzerland, Jan. 2, 2019 /PRNewswire/ -- Roivant Sciences today announced that Vivek Ramaswamy, Founder and Chief Executive Officer of Roivant, will present an overview of the business as well as new data updates from private companies in the Roivant family at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
Dec 20, 2018 07:30 am ET
Myovant Sciences to Present at the 37th Annual J.P. Morgan Healthcare Conference
BASEL, Switzerland, Dec. 20, 2018 /PRNewswire/ -- Myovant Sciences (NYSE: MYOV), a leading clinical-stage biopharmaceutical company focused on women's health and endocrine diseases, today announced that Lynn Seely, M.D., President and Chief Executive Officer of Myovant Sciences, will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The presentation will begin at 9:00 a.m. PT on Tuesday, January 8, 2019 at the Westin St. Francis, followed by a Q&A session at 9:30 a.m. PT.
Nov 15, 2018 07:30 am ET
Myovant Sciences to Participate in Two Upcoming Investor Conferences
BASEL, Switzerland, Nov. 15, 2018 /PRNewswire/ -- Myovant Sciences (NYSE: MYOV), a leading clinical-stage biopharmaceutical company focused on women's health and endocrine diseases, today announced its participation in the following upcoming investor conferences:  
Nov 14, 2018 07:30 am ET
Recent Analysis Shows Atlas Financial, Royal Dutch Shell, Vaalco Energy, Myovant Sciences, Aerpio Pharmaceuticals, and Wheeler Real Estate Investment Trust Market Influences — Renewed Outlook, Key Dri
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Atlas Financial Holdings, Inc. (NASDAQ:AFH), Royal Dutch Shell PLC...
Nov 08, 2018 03:05 pm ET
Myovant Provides Corporate Updates and Reports Financial Results for Second Fiscal Quarter Ended September 30, 2018
BASEL, Switzerland, Nov. 8, 2018 /PRNewswire/ -- Myovant Sciences (NYSE: MYOV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of women's health and endocrine diseases, today announced corporate updates and reported financial results for the second fiscal quarter ended September 30, 2018.
Nov 07, 2018 07:30 am ET
Myovant Strengthens Management Team and Adds New Directors to the Board
BASEL, Switzerland, Nov. 7, 2018 /PRNewswire/ -- Myovant Sciences, Ltd. (NYSE: MYOV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health and endocrine diseases, today announced that Kim Sablich, formerly Vice President of Primary Care Marketing in the United States for GlaxoSmithKline (GSK), will join Myovant Sciences as Chief Commercial Officer, and Jeff Nornhold, formerly Senior Vice President of Technical Operations for Impax Laboratories (now Amneal Pharmaceuticals, Inc.), has joined Myovant as Senior Vice Presiden
Oct 24, 2018 08:30 am ET
Myovant Sciences Announces Completion of Enrollment in Phase 3 HERO Trial of Relugolix in Men with Advanced Prostate Cancer
BASEL, Switzerland, Oct. 24, 2018 /PRNewswire/ -- Myovant Sciences (NYSE: MYOV) today announced it has completed patient enrollment in its pivotal Phase 3 clinical trial, HERO, which is evaluating the safety and efficacy of relugolix for the treatment of men with advanced prostate cancer. The HERO study is designed to support approval by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Japanese Pharmaceuticals and Medical Devices Agency.
Oct 10, 2018 01:45 pm ET
Myovant Announces Presentation of Data from Phase 1 Trial of MVT-602 at 2018 American Society for Reproductive Medicine (ASRM) Annual Congress
BASEL, Switzerland, Oct. 10, 2018 /PRNewswire/ -- Myovant Sciences (NYSE: MYOV) today announced the presentation of data from a Phase 1 trial of MVT-602, a novel kisspeptin-1 receptor agonist in development as a potential treatment for female infertility in women as part of assisted reproduction, such as in vitro fertilization (IVF). Results of the study showed that administration of MVT-602 in healthy premenopausal women in the follicular phase produced a dose-related increase in luteinizing hormone concentrations and expected effects on follicle-stimulating hormone and estradiol. The findi
Oct 08, 2018 08:30 am ET
Myovant Sciences and Flo Health Partner to Develop Digital Tool to Screen Women for Heavy Menstrual Bleeding
BASEL, Switzerland and REDWOOD CITY, Calif., Oct. 8, 2018 /PRNewswire/ -- Myovant Sciences (NYSE: MYOV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health and endocrine diseases, and Flo Health, a company developing the world's fastest growing artificial intelligence (AI)-driven platform for women's health with 22 million active users, announced today a partnership to create a digital tool to screen for heavy menstrual bleeding. Affecting more than 25 percent of women, heavy menstrual bleeding is associated with disea
Aug 28, 2018 08:30 am ET
Myovant Sciences to Participate in Two Upcoming Investor Conferences
BASEL, Switzerland, Aug. 28, 2018 /PRNewswire/ -- Myovant Sciences (NYSE: MYOV), a leading clinical-stage biopharmaceutical company focused on women's health and endocrine diseases, today announced its participation in the following upcoming investor conferences:  
Aug 07, 2018 04:30 pm ET
Myovant Provides Corporate Update and Reports Financial Results for First Fiscal Quarter Ended June 30, 2018
BASEL, Switzerland, Aug. 7, 2018 /PRNewswire/ -- Myovant Sciences (NYSE: MYOV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of women's health and endocrine diseases, today announced corporate updates and reported financial results for the first fiscal quarter ended June 30, 2018.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.